Founder M. Owen Number of employees +5,000 Type of business Subsidiary of Nestlé | Revenue €1.7 billion in 2013 Website www.galderma.com Founded 1981 | |
 | ||
Industry DermatologyPharmaceuticals CEO Stuart Raetzman (Mar 2015–) Profiles | ||
Bronze farts galderma benzac anti acne cleansing cream
Galderma S.A. is a pharmaceutical subsidiary specializing in the research, development and marketing of dermatological treatments and became a wholly owned subsidiary of Nestlé in 2014.
Contents
About
Galderma was formed in 1981 as a joint venture between Nestlé and L'Oréal. The company, headed by President & CEO Humberto C. Antunes, has 33 affiliates in 100 countries with a worldwide network of distributors and employs more than 5,000 people. The parent company is based in Lausanne, Switzerland, with Corporate Services in Paris-La Défense, France.
The Galderma Code of Ethics lists all applicable legal requirements in the countries where Galderma operates. Galderma S.A. have extensive policies and procedures contained in other supporting documents. talking in terms of environment, social aspects and business ethics..
History
The origins of Galderma date back to 1961 and the founding of the Owen dermatology company in Dallas, Texas, USA by M. Owen.
In 2007, the Galderma Global Corporate Campaign won the Medical Marketing Association's International Award of Excellence.
In 2010, sales reached 1.2 billion euros, an increase of 16.1% over 2009.
In 2011, Galderma acquired Q-Med, a Swedish medical-device company.
In 2014, Nestlé buys back all the shares from L'Oréal, thus creating a new unit into Nestlé group called: "Nestle Skin Health". The transaction has a value of €3.1 billion, (USD$4.23 billion), was paid by Nestlé with 21.2 million L'Oréal shares. L'Oréal will pay €3.4 billion (USD$4.63 billion) for the remaining 27.3 million shares.
Activities
Galderma provides a range of products used to treat acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and skin senescence. Galderma’s products sell in more than 70 countries.
The company invests substantially in research and development and sources new treatments from its own activities and from its partnerships with others. It divides its research and development departments between four sites:
Galderma has manufacturing facilities at the following locations:
The French and Canadian plants have grown in order to improve and increase production capacity. As of 2011 the four sites combined produced over 100 million units.